Clinical Trial Update: Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial evaluating tadalafil for Raynaud's phenomenon in patients with scleroderma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon
• Systemic Sclerosis

Drugs mentioned

• TADALAFIL (TADALAFIL)

Snippet

Sponsor: Sanjay Gandhi Postgraduate Institute of Medical Sciences | Conditions: Raynaud Disease | Phase 3 | Status: COMPLETED